293 related articles for article (PubMed ID: 16672401)
1. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
Panackal AA; Gribskov JL; Staab JF; Kirby KA; Rinaldi M; Marr KA
J Clin Microbiol; 2006 May; 44(5):1740-3. PubMed ID: 16672401
[TBL] [Abstract][Full Text] [Related]
2. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
Shin JH; Chae MJ; Song JW; Jung SI; Cho D; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
J Clin Microbiol; 2007 Aug; 45(8):2385-91. PubMed ID: 17581937
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
4. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
Magill SS; Shields C; Sears CL; Choti M; Merz WG
J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
[TBL] [Abstract][Full Text] [Related]
5. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
6. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
7. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Samra Z; Yardeni M; Peled N; Bishara J
Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
[TBL] [Abstract][Full Text] [Related]
8. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Barton R; Bijie H; Bille J; Chang SC; da Luz Martins M; Duse A; Dzierzanowska D; Ellis D; Finquelievich J; Gould I; Gur D; Hoosen A; Lee K; Mallatova N; Mallie M; Peng NG; Petrikos G; Santiago A; Trupl J; VanDen Abeele AM; Wadula J; Zaidi M;
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
[TBL] [Abstract][Full Text] [Related]
9. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).
Safdar A; Chaturvedi V; Koll BS; Larone DH; Perlin DS; Armstrong D
Antimicrob Agents Chemother; 2002 Oct; 46(10):3268-72. PubMed ID: 12234857
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
13. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
15. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
Alexander BD; Schell WA; Miller JL; Long GD; Perfect JR
Transplantation; 2005 Sep; 80(6):868-71. PubMed ID: 16210978
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
17. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
Lee JS; Shin JH; Lee K; Kim MN; Shin BM; Uh Y; Lee WG; Lee HS; Chang CL; Kim SH; Shin MG; Suh SP; Ryang DW
Yonsei Med J; 2007 Oct; 48(5):779-86. PubMed ID: 17963334
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
Pfaller MA; Diekema DJ; Boyken L; Messer SA; Tendolkar S; Hollis RJ
J Clin Microbiol; 2003 May; 41(5):1875-80. PubMed ID: 12734220
[TBL] [Abstract][Full Text] [Related]
19. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
[TBL] [Abstract][Full Text] [Related]
20. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
